On June 15, 2017, Ryan Lynch, Corporate Controller of Concert Pharmaceuticals, Inc. (the “Corporation”) was appointed by the Board of Directors of the Corporation as the Principal Financial Officer and Principal Accounting Officer.

About Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company’s product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine.

POPULAR CATEGORY

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions.
At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices.
Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.